The Janssen Pharmaceutical Companies of Johnson & Johnson announced the World Health Organization (WHO) will include abiraterone acetate (ZYTIGA®) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medic